Key Inclusion Criteria:

          -  Histologically or cytologically confirmed recurrent or metastatic HPV associated tumor
             (cervical, oropharyngeal, vulvar, vaginal, anal, or penile) with documented disease
             progression.

          -  Arm 1, Phase 1 dose escalation: Cervical, HPV+ oropharyngeal, vulvar, vaginal, anal,
             or penile

          -  Arm 1, Cohort A: Cervical cancer

          -  Arm 1, Cohort B: HPV+ Oropharyngeal cancer

          -  Arm 2 Phase 1 dose escalation and Cohort C: Cervical, oropharyngeal, vulvar, vaginal,
             anal, or penile

          -  Failed, refused or intolerant to systemic therapy

          -  Measurable disease based on RECIST 1.1

          -  At least one tumor mass amenable to core needle biopsy

          -  Arm 2 only: At least one tumor judged as being safely injectable

          -  ECOG performance status 0 or 1

          -  Demonstrate adequate organ function

          -  Additional Inclusion criteria exist

        Key Exclusion Criteria:

          -  Prior systemic therapy within 4 weeks.

          -  Patients receiving prior XRT must have recovered from any acute toxicity.

          -  Currently receiving/received experimental therapy within 4 weeks.

          -  Prior treatment with any HPV vaccine therapy for cancer.

          -  Requires use of anti-platelet or anti-coagulant therapy that cannot be safely
             suspended for per protocol biopsies or intra-tumoral injections.

          -  Known active CNS metastases and/or carcinomatous meningitis.

          -  Clinically significant tumor invasion/ rapidly accumulating ascites, pericardial or
             pleural effusions.

          -  Active infection requiring systemic therapy.

          -  Active autoimmune disease that has required systemic therapy in the past 2 years.

          -  Conditions likely to have resulted in splenic dysfunction.

          -  Known HIV/AIDS, active HBV or HCV infection.

          -  Received prior treatment with vesicular stomatitis (VSV) viral vector.

          -  Received immunosuppressive medication within 4 weeks. (>10mg/day prednisone)

          -  ≥ Grade 2 dyspnea and/or require supplemental oxygen

          -  Known intolerance to anti-PD-1 or anti-PD-L1 antibody therapy

          -  Additional Exclusion criteria exist

        Exclusion Criteria Household Contacts:

          -  Patients with household contacts meeting any of the following criteria are ineligible
             for study entry unless alternate living arrangements can be made, while under contact
             precautions.

          -  Women who are pregnant or nursing an infant

          -  Children < 1 year old

          -  Individuals who are severely immunocompromised

          -  Contact precautions are from initial treatment with MG1-E6E7 to 7 days after the last
             dose of MG1-E6E7